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Findings: Urine survivin expression detected bladder can-
cer with higher sensitivity (85.25%, 95% CI 73.8–93.0%) and speci-
ficity (100.00%, 90.4–100.0%) than urine cytology, which showed
52.29% sensitivity (42.5–61.9%) and 87.88% specificity (77.5–
94.6%). In the 62 treated patients, urine survivin expression had
22.92% sensitivity (12.0–37.3%) and 92.86% specificity (66.1–
98.8%) for detecting bladder cancer. Surprisingly, among the 62
treated patients, 13 (21%) showed survivin expression. Follow-
up of these patients for 1 year revealed recurrence of TCC in nine
patients (69%).
Interpretation: This study shows the clinical utility of survi-
vin expression in new or recurrent bladder cancer, and in patients
with a negative biopsy receiving follow-up care. Thus, highly
sensitive and specific determination of survivin in exfoliated cells
in urine, by use of qRT-PCR, seems to provide a simple,
non-invasive diagnostic biomarker for routine screening of blad-
der cancer.
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OP11 PROGNOSTIC SIGNIFICANCE OF F-18 FDG-PET/CT IMAGES
IN CURATIVELY RESECTED GASTRIC CANCER
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Background: The role of F-18 FDG-PET/CT in gastric cancer is
limited in some cases by gastric histology. This retrospective
study was designed to assess the accuracy of F-18 FDG-PET/CT
for imaging stomach cancer, and its correlation with other
clinicopathological findings, including its role as a prognostic
factor.
Methods: 431 patients who underwent F-18 FDG-PET/CT before
surgery for gastric cancer were included in this study, from
December, 2006, to May, 2010. The mean age was 62 years (SD
11.6) and the male-to-female ratio was 265:167. Patients were
divided into three groups according to the maximal standardised
uptake value (SUVmax) of the tumour. All patients medical
records were reviewed, including surgical and pathological
results. All parameters were compared by one-way ANOVA and
v2-test. Survival curves were calculated using the Kaplan–Meier
method, and the statistical difference in prognosis was analysed
using a generalised log-rank test.
Findings The mean tumour SUVmax was 6.51 in surgically
treated stomach cancer. Group 1 included 175 patients with SUV-
max of 0, group 2 was 124 patients with SUVmax lower than 5,
and group 3 was 133 patients with SUVmaxP 5. The intensity
of FDG uptake correlated with tumour size (r2 = 0.103, p < 0.001),
and showed significant difference according to TNM
stage, tumour grade, lymphovascular invasion, nerve invasion,
and sex. SUVmax was higher in poorly differentiated tumours
and in men. Apart from SUVmax, all of the pathological parame-
ters, including TNM stage, tumour grade, lymphovascular inva-
sion, and nerve invasion, were not associated with median
survival.
Interpretation: The SUVmax of F-18 FDG-PET/CT of surgically
treated gastric cancer correlated with TNM stage, tumour grade,
lymphovascular invasion, nerve invasion, and sex. SUVmax also
correlated with median survival.
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OP12 XPD/ERCC2 CODON 751 AND XRCC1 CODON 280 POLY-
MORPHISMS AND THE RISK OF NASOPHARYNGEAL CARCINOMA
IN MALAYSIA
V. Shaneeta a, M.S. Lye a,*, P.P. Chong a, Y.Y. Yap a, I. Hairuzah a,
C.C. Lim b. a Universiti Putra Malaysia, Selangor, Malaysia. b Hospital
Kuala Lumpur, Kuala Lumpur, Malaysia
Background: According to the Malaysian National Cancer Regis-
try, nasopharyngeal carcinoma (NPC) was the third most common
cancer among men in peninsular Malaysia in 2006. Variations in
specific DNA repair genes alter individual cancer risk, and the
DNA repair system has a crucial role in maintaining the integrity
of the human genome. Xeroderma pigmentosum complementa-
tion group D (XPD)/excision repair cross-complementing group 2
(ERCC2) encodes a helicase that participates in nucleotide excision
repair. This variant allele of polymorphism XPD Lys751Gln has
been associated with increased DNA adduct levels, and with low
DNA repair capacity. Another gene, the X-ray cross complementing
group 1 (XRCC1) encodes a protein involved in the base-excision
repair pathway. Arg280His is located in the nuclear antigen-bind-
ing region of proliferating cells. Reports suggest that an Arg280His
variant protein is defective in localisation of damaged sites in the
chromosome, thereby reducing the efficiency of base excision
repair. In this study, we investigated the possible association of
these two polymorphisms with an increased risk of developing
NPC in the Malaysian population.
Methods: A molecular epidemiological study was done using a
hospital-based case-control study design. A total of 113 cases and
130 controls were available for study, matched for age, sex, and
ethnicity. Single nucleotide polymorphism (SNP) genotyping was
carried out using a PCR-restriction fragment length polymor-
phism (RFLP) method.
Findings: A total of 113 cases and 130 controls were analysed.
The frequency of the XPD codon 751 homozygous wild-type Lys/
Lys genotype was 87.6% (99/113) in cases and 73.9% (96/130) in
controls; the heterozygous Lys/Gln genotype was 12.4% (14/113)
in cases and 25.4% (33/130) in controls; and the Gln/Gln genotype
was 0% (0/113) in cases and 0.7% (1/130) in controls. For XPD/
ERCC2 codon 751, an odds ratio (OR) of 2.41 was observed (95%
CI 1.17– 4.97, p = 0.017). Risk of NPC was nearly two and a half
times higher for individuals with the homozygous wild-type
Lys/Lys grenotype than for the heterozygous Lys/Gln genotype,
adjusted for age, sex, and ethnicity. To our knowledge, there have
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been no documented reports of the association between XPD-
Lys751Gln and nasopharyngeal carcinoma risk until now. The fre-
quency of the XRCC1 codon 280 homozygous wild-type Arg/Arg
genotype was 77.9% (88/113) in cases and 80.8% (105/130) in con-
trols; the heterozygous Arg/His genotype was 21.3% (24/113) in
cases and 18.5% (24/130) in controls; and the His/His genotype
was 0.8% (1/113) in cases and 0.7% (1/130) in controls. For XRCC1
codon 280 polymorphisms, no significant association between
Arg280His and risk of NPC was found (OR 1.30, 95% CI 0.66–2.57;
p = 0.447).
Interpretation: Risk of NPC was nearly two and a half times
higher for individuals with the homozygous wild-type Lys/Lys
genotype than for the heterozygous Lys/Gln genotype, adjusted
for age, sex, and ethnicity. To our knowledge, there have been
no documented reports of the association between XPDLys751Gln
and nasopharyngeal carcinoma risk until now.
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OP13 NIMOTUZUMAB COMBINED WITH RADIOTHERAPY FOR
OESOPHAGEAL CARCINOMA – A PHASE 2 CLINICAL TRIAL
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Hospital, Tianjin Medical University, Tianjin, China. e Department of
Radiotherapy, LiaoNing Province Cancer Hospital, Shenyang,
China. f Department of Radiotherapy, Beijing Hospital, Beijing,
China. g Biotech Pharmaceuticals Ltd., Beijing, China. h School of
Medicine, Tongji University, Shanghai, China
Background: We evaluated the safety and efficacy of nim-
otuzumab in combination with radiotherapy for oesophageal car-
cinoma (ESO).
Methods: 42 patients with stage II–IVa ESO were randomly
assigned as part of this prospective, phase 2 trial, from November,
2008, to July, 2010. All patients received 50–70 Gy three-dimen-
sional conformal radiotherapy. 200 mg of nimotuzumab was
administered via intravenous infusion once a week during
radiotherapy.
Findings: Primary cancer lesions were located in the upper,
middle, and lower thoracic segments of the oesophagus in 10,
26, and 3 patients, respectively. Nine patients had stage II ESO,
25 had stage III, and eight had stage IVa. All patients received
50–70 Gy of radiation and 37 patients (88.1%) received nim-
otuzumab more than five times. Grade 3 toxicities were nausea
and vomiting (n = 1), oesophagitis (n = 3), skin reactions (n = 4),
and haematological toxicity (n = 1). One patient had an allergic
reaction to nimotuzumab. Four patients (9.5%) had a complete
response, 21 (50%) had a partial response, two (4.8%) had stable
disease, and 15 (35.7%) had progressive disease. The overall
disease control rate was 64.3%. With a median follow-up of 6
months, local recurrence was observed in six patients (14.3%)
and distance metastasis in ten (23.8%). Ten patients died, with
eight possible cancer-related deaths. The median survival time
has not yet been reached. 6-month and 1-year overall survival
rates were 82.4% and 57.8%.
Interpretation: Nimotuzumab in combination with radiother-
apy is well tolerated and effective for treatment of ESO. Long-term
toxicity and long-term efficacy require further evaluation.
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P14 SCREENING FOR GASTRIC-CANCER MICROMETASTASES IN
A SINGLE SENTINEL LYMPH NODE WITH REAL-TIME PCR – A
PRELIMINARY STUDY WITH THE MARUYAMA COMPUTER
SIMULATION
T. Jagric a,*, S. Potrc a, A. Ivanecz a, M. Horvat a, M. Plankl b, T.
Mars b. a Department of Abdominal and General Surgery, University
Medical Centre Maribor, Maribor, Slovenia. b Institute of
Pathophysiology, Faculty of Medicine, University of Ljubljana,
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Background: Sentinel lymph node (SLN) mapping has recently
been introduced in the treatment of gastric cancer. Although
immunohistochemistry and conventional real-time PCR (RT-
qPCR) provide reliable information about micrometastases in
SLNs, they cannot examine large numbers of lymph nodes in a
short time, making them unfeasible for intraoperative use. The
SLN is defined as the first node to receive cancer-cell drainage
from the primary tumour, therefore micrometastases or isolated
tumour cells should first develop in these nodes. In this preli-
minary study, we evaluated the concept of single SLN screenings
for micrometastases by use of the Maruyama computer
program.
Methods: 23 patients were enrolled in our study: nine patients
were included in the control group and 14 in the study group. The
first stained lymph node was analysed with RT-qPCR for carcino-
embryonic antigen and CK-20 expression, as markers for microm-
etastases. Patients characteristics were retrospectively used as
predictors in the Maruyama computer program, to determine
the most likely metastatic site. Results were compared with the
actual staining patterns, and correlations between tumour char-
acteristics and micrometastases were examined.
Findings: 14 patients were found to be N0. Micrometastases
were detected in four patients (28.6%). In 76.9% of cases, extracted
SLNs coincided with lymph nodes predicted by the computer pro-
gram to be the most likely metastatic site. Micrometastases were
more common in Maruyama-predicted lymph nodes. Laurens
histological type distribution, preoperative CA 19-9 values, and
age distribution differed significantly between patients who were
positive and negative for micrometastases.
Interpretation: These results indicate the potential use of a sin-
gle SLN for intraoperative decision making; however, sensitivity
and specificity need to be evaluated in a larger series, supported
by long-term recurrence and survival results.
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